Smith & Nephew Publishes 2025 Annual Report and Calls 2026 AGM

Smith & Nephew Snats ( (SNN) ) just unveiled an announcement.

On 16 March 2026, Smith & Nephew plc announced it had published its 2025 Annual Report, the Notice of its 2026 Annual General Meeting (AGM), the related Form of Proxy, and proposed new Articles of Association, marking a key point in its annual governance and reporting cycle. The company also confirmed that the 2025 Annual Report on Form 20‑F was filed with the U.S. Securities and Exchange Commission the same day, with all documents made accessible via the UK National Storage Mechanism and the company’s website, ensuring regulatory compliance and transparency for shareholders and other stakeholders.

The most recent analyst rating on (SNN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.

The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith & Nephew plc is a UK‑based global medical technology company, best known for its orthopaedics, sports medicine, and advanced wound management products used by healthcare providers worldwide. The group focuses on surgical devices and wound care solutions that support hospitals and clinicians in improving patient outcomes across key therapy areas.

Average Trading Volume: 875,024

Technical Sentiment Signal: Buy

Current Market Cap: $14.04B

See more data about SNN stock on TipRanks’ Stock Analysis page.